POST Online Media Lite Edition


Taiwanese firm develops cancer drug for animals

Staff writer |
A new drug developed by a Taiwanese company Vetco Pharmaceutical to treat cancers in pets has passed double-blind trials and is set to be introduced into the international market.

Article continues below

The results of the double-blind trials proved that the drug TD-B10, developed by Vetco Pharmaceutical can be considered effective in the treatment of animal cancers, Vetco chairman James Chen said at a press conference in Taipei.

Success was achieved after 10 years of research and clinical trials, and the company will now submit the double-blind trial report to the Council of Agriculture (COA) to apply for certification as a veterinary drug, he said.

Last year, TD-B10 was recognized by the U.S. Food and Drug Administration (FDA) as safe compared with other types of animal chemotherapy and it has a good chance of also obtaining FDA certification, Chen said.

Vetco plans to put the drug on the global market by the second half of the year, he said.

The double-blind trials on TD-B10 were carried out by veterinarians at National Taiwan University Veterinary Hospital and the veterinary hospitals of National Chiayi University and National Pingtung University of Science and Technology from Jan. 19 last year.

The trials focused on treating dogs with tumors, Chen said.

What to read next

Cancer Genetics in partnership with AstraZeneca CAMCAR
Pfizer to buy antibiotics business from AstraZeneca
Pfizer hikes U.S. prices for more than 100 drugs